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BACKGROUND Dual antiplatelet therapy with a P2Y12 inhibitor is mandatory in acute coronary syndromes (ACS) undergoing angioplasty. New antiplatelet drugs prasugrel and ticagrelor offer more efficient inhibition compared to clopidogrel. Under P2Y12 inhibitor, platelet reactivity (PR) assessment can predict ischemic and bleeding events. The aim of our study was to compare PR in ACS patients on P2Y12 inhibitors in a real-world setting.
METHODS Platelet reactivity (PR) was prospectively assessed in consecutive patients with recurrent ACS or undergoing high-risk angioplasty. PR was measured 24hrs after last intake of clopidogrel (C) and prasugrel (P), and 12hrs for ticagrelor (T) by flow cytometry measured vasodilatator-stimulated phosphoprotein platelet reactivity index (VASP-PRI) and light transmission agregometry with ADP 20mM (LTA-ADP). High Platelet Reactivity (HPR) was defined as VASP-PRI>50% or LTA-ADP>65% (thresholds previously linked to clinical events). Low Platelet Reactivity (LPR) was defined as VASP-PRI<16% or LTA-ADP<40%.
RESULTS
Six hundred and nineteen patients treated with aspirin and C (n¼269), P (n¼241) or T (n¼109) were included from 01/2011 to 07/ 2013. Mean age was 62AE13yrs., 80% were men and 63% had STEMI. Patients on C were older, more often women and admitted for NSTEMI. Inflammatory parameters were lower in this subgroup (C). Clinical and biological characteristics were similar between patients on P and those on T. HPR was more frequent with C compared to P and T and significantly more frequent with P compared to T (Table 1) . At the opposite, LPR was significantly more frequent in patients treated with T. In multivariate analysis, the significant predictor of HPR with VASP was P (OR¼0.13-CI[0.08-0.22]) or T (OR¼0.01-[0.01-0.09]). The significant predictor of LPR with VASP was T (OR¼3.37-[2.09-5.44]). .007) and the homozygote mutated groups have the lowest ADP inhibition of the three groups variants. However, there were no significant differences in ADP inhibition among the rs553668 genotype groups (50.20AE27.83% vs. 54.09AE29.41% vs. 52.11AE30.00%, P¼0.158). At the multivariable analysis, the presence of the rs11195419 (95%CI: -0.062--2.070, P¼0.039) or rs3750625 (95%CI: -0.068--2.281, P¼0.023) genetic variants was an independent predictor of the ADP inhibition. However, there were no significant differences in the composite clinical outcome across the rs11195419, rs3750625, rs553668 genotype groups at both 6 and 12 months follow-up period(P>0.05).
CONCLUSIONS The presence of mutated alleles of a2A -AR genetic variants (rs11195419, rs3750625) except rs553668 is associated with decreased ADP-induced platelet reactivity in Chinese patients with DAPT after percutaneous coronary intervention. However, none of the a2A -AR genetic variants significantly influenced the clinical outcomes of DAPT in these patients. 
